



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

16th March 2026
IOLCP/CGC/2026

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

Subject: Clarification for Financial Results- IOLCP

Dear Sir/ Madam,

With reference to your email dated 11th March 2026, regarding the observation that the financial results for Q3 ended 31st December 2025, submitted on 11th February 2026, are not in the format prescribed under Schedule III of the Companies Act, 2013 or as per the Indian Accounting Standards, and that the Standalone and Consolidated results reflect the same figures.

We would like to clarify that both the Standalone and Consolidated Financial Results have been prepared in compliance with the Indian Accounting Standards and have been submitted to the Exchanges in the format prescribed under Schedule III of the Companies Act, 2013. There has been no deviation from the prescribed format.

Further, the similarity in figures between the Standalone and Consolidated results arises because, except for one subsidiary incorporated under Section 8 of the Companies Act, none of the subsidiary companies have commenced business operations during the reporting period. Consequently, the differences are limited to profit, depreciation, and other expense items.

Kindly consider above explanation and take on record the financial results for Q3 ended 31st December 2025, as submitted on 11th February 2026.

Thanking You,

Yours faithfully,

For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh

Sr Vice President and Company Secretary